Int J Clin Exp Patho
-
Int J Clin Exp Patho · Jan 2021
Long non-coding RNA CYTOR regulates proliferation and metastasis of colon cancer cells through regulating miRNA-105/PTEN axis.
Colon cancer is a common malignancy, and its incidence and mortality have been increasing in recent years. This study aims to explore the regulation of long non-coding RNA CYTOR on proliferation and metastasis of colon cancer cells through miRNA-105/PTEN axis. Real-time quantitative PCR (qRT-PCR) disclosed that expression of CYTOR was significantly decreased in colon cancer tissues, compared with that of adjacent normal tissues, while miRNA-105 was significantly increased. ⋯ Additionally, the proliferation, migration, and invasion rates of the LoVo cells in miR-105 inhibition group were significantly slower. The Starbase database predicted the targeting of miR-105 by CYTOR, and qRT-PCR and dual luciferase reporter gene method were used to verify the targeting relationship of CYTOR and miRNA-105/PTEN axis. In conclusion, CYTOR can inhibit the proliferation and metastasis of colon cancer cells through targeted inhibition of the miR-105/PTEN axis.
-
Int J Clin Exp Patho · Jan 2020
Downregulated miR-203 attenuates IL-β, IL-6, and TNF-α activation in TRAF6-treated human renal mesangial and tubular epithelial cells.
Circulating microRNAs (miRNAs) are attracting major interest as novel non-invasive biomarkers for human autoimmune diseases including lupus nephritis (LN). A previous study showed that altered miR-203 expression may provide highly diagnostic for systemic lupus erythematosus. However, whether miR-203 is a diagnostic biomarker for LN is still unknown. ⋯ Furthermore, circulating miR-203 expression was positively correlated with the serum concentrations of C3 and C4, and negatively correlated with the serum expression of IL-1β, IL-6, and TNF-α in active LN patients. In addition, transfection of HRMCs and HK-2 cells with miR-203 mimics could suppress TRAF6-induced IL-β, IL-6, or TNF-α expression compared to cells treated with the mimics control group. In summary, decreased circulating miR-203 might be a candidate diagnostic biomarker for human active LN, and it attenuated IL-β, IL-6, and TNF-α activation in TRAF6-treated HRMCs and HK-2 cells.
-
Int J Clin Exp Patho · Jan 2019
ReviewSerum microRNA-195 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis.
Serum microRNA-195 (miR-195) expression has been shown to be significantly up-regulated in breast cancer, which implies that it could be a useful biomarker in the early detection of breast cancer. Hence, we performed this meta-analysis to investigate the diagnostic value of miR-195 for breast cancer. Relevant articles were collected from PubMed, Scopus, Embase, the Cochrane Library, BioMed Central, ISI Web of Knowledge, China National Knowledge Infrastructure, Wan Fang Data and Technology of Chongqing databases, from inception to May 24, 2019, by two independent researchers. ⋯ The pooled results for sensitivity, specificity and DOR were 0.79 (95% CI: 0.75-0.83), 0.86 (95% CI: 0.82-0.90) and 32.05 (95% CI: 17.04-60.30), respectively; positive and negative likelihood ratios were 5.18 and 0.20, and AUC was 0.9197 (95% CI: 0.86-0.91). In addition, heterogeneity was clearly apparent but was not caused by the threshold effect. In summary, this meta-analysis revealed that miR-195 may be suitable as a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and further investigations are needed to demonstrate its clinical application value.
-
Int J Clin Exp Patho · Jan 2019
MicroRNA-124 represents a novel diagnostic marker in human lupus nephritis and plays an inhibitory effect on the growth and inflammation of renal mesangial cells by targeting TRAF6.
microRNAs (miRs) are short non-coding RNAs that function as guide molecules in RNA silencing by inducing mRNA degradation or blocking protein translation. Increasing evidence has shown that miRNAs play an important role in regulating the pathological process of lupus nephritis (LN), but the precise role of miR-124 in LN is still unknown. Here, we found that miR-124 expression is significantly reduced in patients with active LN compared with those patients with non-active LN and the absence of LN. ⋯ Moreover, a dual luciferase assay showed that TRAF6 was a direct target of miR-124, and the expression of TRAF6 was suppressed by miR-124 through direct binding to the 3'-UTR of mRNA. Mechanistic studies demonstrated that the over-expression of TRAF6 could abrogate miR-124-related effects on cell proliferation, apoptosis and the synthesis of inflammatory factors in HRMCs. Taken together, these findings indicate that downregulated miR-124 represents a novel diagnostic marker in human LN and plays an inhibitory effect on the growth and inflammation of renal mesangial cells by targeting TRAF6.
-
Int J Clin Exp Patho · Jan 2018
Correlation between clinicopathological features and KRAS, NRAS, and BRAF mutation status in Chinese colorectal cancer patients.
This study was retrospectively performed to analyze correlations between clinicopathological features of colorectal cancer (CRC) and mutations in KRAS, NRAS, and BRAF in Chinese patients, and to assess the importance of detecting additional mutations in KRAS exons 3 and 4 and NRAS in patients with CRC. RAS (KRAS and NRAS) and BRAF mutations were detected in 715 and 655 patients respectively. The mutation rate of RAS (KRAS or NRAS) was 45.6% (326/715). ⋯ Female patients had a higher BRAF (exon 15) mutation rate than male patients (5.1% vs. 1.1%, P=0.017). Detection of both KRAS and NRAS mutations is useful for selecting patients who will benefit from anti-EGFR monoclonal antibody therapy. KRAS mutations were more frequent in patients with mucinous adenocarcinoma/signet ring cell CRC, whereas BRAF mutations were more common in female patients with CRC.